These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 34475850)

  • 1. FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale.
    Adam P; Kircher S; Sbiera I; Koehler VF; Berg E; Knösel T; Sandner B; Fenske WK; Bläker H; Smaxwil C; Zielke A; Sipos B; Allelein S; Schott M; Dierks C; Spitzweg C; Fassnacht M; Kroiss M
    Front Endocrinol (Lausanne); 2021; 12():712107. PubMed ID: 34475850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.
    Dierks C; Seufert J; Aumann K; Ruf J; Klein C; Kiefer S; Rassner M; Boerries M; Zielke A; la Rosee P; Meyer PT; Kroiss M; Weißenberger C; Schumacher T; Metzger P; Weiss H; Smaxwil C; Laubner K; Duyster J; von Bubnoff N; Miething C; Thomusch O
    Thyroid; 2021 Jul; 31(7):1076-1085. PubMed ID: 33509020
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer.
    Gunda V; Gigliotti B; Ashry T; Ndishabandi D; McCarthy M; Zhou Z; Amin S; Lee KE; Stork T; Wirth L; Freeman GJ; Alessandrini A; Parangi S
    Int J Cancer; 2019 May; 144(9):2266-2278. PubMed ID: 30515783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer.
    Cantara S; Bertelli E; Occhini R; Regoli M; Brilli L; Pacini F; Castagna MG; Toti P
    Endocrine; 2019 Apr; 64(1):122-129. PubMed ID: 30762153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 expression in rare and aggressive thyroid cancers: A preliminary investigation for a role of immunotherapy.
    Boruah M; Gaddam P; Agarwal S; Mir RA; Gupta R; Sharma MC; S Deo SV; Nilima N
    J Cancer Res Ther; 2023; 19(2):312-320. PubMed ID: 37006068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Profiling of Advanced Thyroid Cancers Using Fluorescent Multiplex Immunohistochemistry.
    Ahn J; Jin M; Song E; Ryu YM; Song DE; Kim SY; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim WG
    Thyroid; 2021 Jan; 31(1):61-67. PubMed ID: 32611231
    [No Abstract]   [Full Text] [Related]  

  • 7. PD-L1 Expression and Its Modulating Factors in Anaplastic Thyroid Carcinoma: A Multi-institutional Study.
    Agarwal S; Jung CK; Gaddam P; Hirokawa M; Higashiyama T; Hang JF; Lai WA; Keelawat S; Liu Z; Na HY; Park SY; Fukuoka J; Satoh S; Mussazhanova Z; Nakashima M; Kakudo K; Bychkov A
    Am J Surg Pathol; 2024 Oct; 48(10):1233-1244. PubMed ID: 39004795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.
    Brauner E; Gunda V; Vanden Borre P; Zurakowski D; Kim YS; Dennett KV; Amin S; Freeman GJ; Parangi S
    Oncotarget; 2016 Mar; 7(13):17194-211. PubMed ID: 26943572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 and B7-H3 are Effective Prognostic Factors and Potential Therapeutic Targets for High-Risk Thyroid Cancer.
    Zhu X; Hu C; Zhang Z; Zhu Y; Liu W; Zheng B; Feng X; Lu H
    Endocr Pathol; 2024 Sep; 35(3):230-244. PubMed ID: 39102163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma.
    Rosenbaum MW; Gigliotti BJ; Pai SI; Parangi S; Wachtel H; Mino-Kenudson M; Gunda V; Faquin WC
    Endocr Pathol; 2018 Mar; 29(1):59-67. PubMed ID: 29372535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer.
    Gray KD; McCloskey JE; Vedvyas Y; Kalloo OR; Eshaky SE; Yang Y; Shevlin E; Zaman M; Ullmann TM; Liang H; Stefanova D; Christos PJ; Scognamiglio T; Tassler AB; Zarnegar R; Fahey TJ; Jin MM; Min IM
    Clin Cancer Res; 2020 Nov; 26(22):6003-6016. PubMed ID: 32887724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma.
    Iyer PC; Dadu R; Gule-Monroe M; Busaidy NL; Ferrarotto R; Habra MA; Zafereo M; Williams MD; Gunn GB; Grosu H; Skinner HD; Sturgis EM; Gross N; Cabanillas ME
    J Immunother Cancer; 2018 Jul; 6(1):68. PubMed ID: 29996921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 expression and immune cells in anaplastic carcinoma and poorly differentiated carcinoma of the human thyroid gland: A retrospective study.
    Cameselle-García S; Abdulkader-Sande S; Sánchez-Ares M; Rodríguez-Carnero G; Garcia-Gómez J; Gude-Sampedro F; Abdulkader-Nallib I; Cameselle-Teijeiro JM
    Oncol Lett; 2021 Jul; 22(1):553. PubMed ID: 34093774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study.
    Soll D; Bischoff P; Frisch A; Jensen M; Karadeniz Z; Mogl MT; Horst D; Penzkofer T; Spranger J; Keilholz U; Mai K
    BMC Endocr Disord; 2024 Feb; 24(1):25. PubMed ID: 38383419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing.
    Duan H; Li Y; Hu P; Gao J; Ying J; Xu W; Zhao D; Wang Z; Ye J; Lizaso A; He Y; Wu H; Liang Z
    Histopathology; 2019 Dec; 75(6):890-899. PubMed ID: 31230400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
    Iñiguez-Ariza NM; Ryder MM; Hilger CR; Bible KC
    Thyroid; 2017 Jul; 27(7):923-927. PubMed ID: 28471306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Boosted abscopal effect from radiotherapy and pembrolizumab in anaplastic thyroid cancer: a mini-review and case report.
    Goh D; Lim KH; Sudirman SRB; Ang MK; Chua MLK; Lim CM
    Chin Clin Oncol; 2023 Oct; 12(5):57. PubMed ID: 37964542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of Lenvatinib and Pembrolizumab as Salvage Treatment for Paucicellular Variant of Anaplastic Thyroid Cancer: A Case Report.
    Luongo C; Porcelli T; Sessa F; De Stefano MA; Scavuzzo F; Damiano V; Klain M; Bellevicine C; Matano E; Troncone G; Schlumberger M; Salvatore D
    Curr Oncol; 2021 Dec; 28(6):5401-5407. PubMed ID: 34940089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Protein Expression Defines the Prognosis of Advanced Thyroid Carcinoma.
    Luo Y; Yang YC; Shen CK; Ma B; Xu WB; Wang QF; Zhang Y; Liao T; Wei WJ; Wang Y
    Front Endocrinol (Lausanne); 2022; 13():859013. PubMed ID: 35574031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
    Takahashi S; Kiyota N; Yamazaki T; Chayahara N; Nakano K; Inagaki L; Toda K; Enokida T; Minami H; Imamura Y; Fukuda N; Sasaki T; Suzuki T; Ikezawa H; Dutcus CE; Tahara M
    Future Oncol; 2019 Mar; 15(7):717-726. PubMed ID: 30638399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.